Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL(+) acute lymphoblastic leukemia

Tyrosine kinase inhibitors (TKIs) are used as a frontline therapy for BCR-ABL(+) acute lymphoblastic leukemia (ALL). However, resistance to TKI therapy arises rapidly, and its underlying molecular mechanisms are poorly understood. In this study, we identified a novel cascade of events initiated by T...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood
Κύριοι συγγραφείς: Mallampati, Saradhi, Leng, Xiaohong, Ma, Haiqing, Zeng, Jianfang, Li, June, Wang, Haiying, Lin, Kevin, Lu, Yue, Yang, Yang, Sun, Baohua, Gong, Yun, Lee, Ju-Seog, Konopleva, Marina, Andreeff, Michael, Arlinghaus, Ralph B., Cai, Zhen, Fang, Bingliang, Shen, Haifa, Han, Xin, Hirsch-Ginsberg, Cheryl F., Gao, Xiaolian, Paranjape, Anurag N., Mani, Sendurai A., Clise-Dwyer, Karen, Sun, Xiaoping
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2015
Θέματα:
Lymphoid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424418/
https://ncbi.nlm.nih.gov/pubmed/25712988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-576421
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια